Patients with uHCC and Child-Pugh B8/9 also benefit from a combination of antiangiogenic agents and PD-1 inhibitors: a multicenter real-world study

Patients with uHCC and Child-Pugh B8/9 also benefit from a combination of antiangiogenic agents and PD-1 inhibitors: a multicenter real-world study

Background and purpose: Patients with unresectable hepatocellular carcinoma (uHCC) and Child-Pugh grade B face limited treatment options and poor outcomes. This study aims to evaluate whether the effect and safety of combining tyrosine kinase inhibitors (TKIs) with progressive disease (PD)-1 inhibit...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoyan Ding, Xue Yin, Linlin Zheng, Lin Zhou, Junke Hu, Wei Sun, Lei Sun, Yanjun Shen, Ying Teng, Yawen Xu, Wendong Li, Mei Liu, Jinglong Chen
Format: Article
Language:English
Published: Medical Journals Sweden 2025-05-01
Series:Acta Oncologica
Subjects:
Hepatocellular Carcinoma
Lenvatinib
Sorafenib
Immune Checkpoint Inhibitors
Child-Pugh B
Online Access:https://medicaljournalssweden.se/actaoncologica/article/view/42652
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://medicaljournalssweden.se/actaoncologica/article/view/42652

Similar Items